Clevr Blends, Cymbiotika, and the Quiet Funding Wave Hitting Functional Beverages
Five brands raised a combined $90M in Q1 2026 without a single press release. We track where the money went, which VCs are doubling down, and which brands are next.
Something unusual happened in January 2026. Five functional beverage and supplement brands closed funding rounds totaling over $90 million — and not one of them issued a press release. No TechCrunch coverage. No Forbes profile. Just wire transfers, cap table updates, and brands quietly getting back to work.
This is the new normal in consumer CPG fundraising. After a brutal 2023–2024 correction that wiped out overvalued brands and burned retail investors, the smart money returned to the category with a very different posture: smaller checks, quieter terms, and a sharp focus on brands that can demonstrate revenue per dollar of marketing spent.
The Brands That Raised
Clevr Blends closed a $12M Series B extension led by existing investors. Founded by Hannah Mendoza, Clevr has built a loyal DTC following around its functional latte blends — adaptogens, mushrooms, and ceremonial cacao positioned at the premium end of the morning ritual market. Their Shopify revenue grew 34% year-over-year in 2025, and their Amazon presence — while intentionally small — runs at roughly $180K per month. The new capital goes toward retail expansion: they are currently in Whole Foods nationally and are in active conversations with Erewhon and select regional natural grocery chains.
Cymbiotika raised a $22M growth round from a combination of family offices and a single institutional investor. The San Diego-based brand has become one of the most vertically integrated supplement companies in the DTC space — they manufacture the majority of their products in-house, which gives them margins that most supplement brands cannot touch. We estimate their gross margin sits between 68–72%, compared to the category average of 52%. With $58M in estimated annual revenue across DTC and Amazon, Cymbiotika's new capital is earmarked for a retail rollout and an international expansion into the EU and Australia.
The Investor Thesis Behind the Wave
We spoke with three investors who have made bets in functional beverages over the past 12 months. None would go on record, but the thesis was consistent across all three conversations:
"The category correction was necessary. The brands that survived it aren't just alive — they have better unit economics, more loyal customer bases, and far less competitive pressure from zombie brands that raised too much and spent it on Meta ads that didn't work."
The new framework for what makes a fundable functional brand in 2026 looks something like this:
- LTV:CAC above 3.5x — brands that acquired customers through Meta/Google at 2023 prices and retained them are now sitting on assets that are difficult to replicate
- Multi-channel presence — pure DTC brands are being discounted. Investors want to see Amazon velocity and at least one retail anchor (Whole Foods, Target, or Costco)
- Ingredient differentiation — not just "adaptogens" or "probiotics" but a defensible ingredient story with clinical backing or a proprietary form
- Gross margins above 60% — anything below that in the supplement category is a red flag at the Series A and beyond
Which Brands Are Next
Based on the revenue and growth data we track at Pulsse, we are watching three brands that fit the investor profile above and are likely to raise in Q2 or Q3 2026:
Alice Mushrooms has grown DTC revenue 89% year-over-year and has Amazon traction with two core SKUs clearing $40K per month each. Their functional chocolate positioning is genuinely differentiated, and the brand's co-founder has a media profile that drives earned press without paid spend.
Everyday Dose has one of the most remarkable DTC conversion rates in the category — north of 4% on their core landing page — driven by a before/after coffee ritual narrative that converts extremely well. They are at approximately $18M in annual revenue and growing fast enough to be a compelling Series A target by mid-year.
Hiyo is the non-alcoholic social beverage play we are watching most closely. With distribution in 15,000+ doors and a monthly Amazon run rate of $290K, they have the multi-channel proof that 2026 investors want to see.
The funding wave is not over. It is just moving faster and quieter than it used to.